European Journal of Cancer
Volume 46, Issue 2 , Pages 348-354 , January 2010

EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma

  • Alba A. Brandes

      Affiliations

    • Bellaria and Maggiore Hospitals, Bologna, Department of Medical Oncology, Italy
    • Corresponding Author InformationCorresponding author: Address: Medical Oncology, Bellaria and Maggiore Hospitals, Azienda ASL Bologna, Via Altura 3, Bologna, Italy. Tel.: +39 0516225101; fax: +39 0516225057.
    • ,
  • Roger Stupp

      Affiliations

    • Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland
    • ,
  • Peter Hau

      Affiliations

    • Department of Neurology, University of Regensburg, Germany
    • ,
  • Denis Lacombe

      Affiliations

    • EORTC – European Organization for Research and Treatment of Cancer Data Center, Bruxelles, Belgium
    • ,
  • Thierry Gorlia

      Affiliations

    • EORTC – European Organization for Research and Treatment of Cancer Data Center, Bruxelles, Belgium
    • ,
  • Alicia Tosoni

      Affiliations

    • Bellaria and Maggiore Hospitals, Bologna, Department of Medical Oncology, Italy
    • ,
  • Renè O. Mirimanoff

      Affiliations

    • Department of Radiation Oncology, Lausanne, Switzerland
    • ,
  • Johan M. Kros

      Affiliations

    • Department of Pathology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    • ,
  • Martin J. van den Bent

      Affiliations

    • Department of Neuro-Oncology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands

Received 3 September 2009 ,Revised 22 October 2009 ,Accepted 29 October 2009.

References 

  1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996
  2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;
  3. Reardon DA, Friedman AH, Yung WK, et al. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). In: ASCO annual meeting; 2004. p. 1513.
  4. Abdollahi A, Lipson KE, Han X, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 2003;63:3755–3763
  5. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59:3374–3378
  6. Parthymou A, Kardamakis D, Pavlopoulos I, et al. Irradiated C6 glioma cells induce angiogenesis in vivo and activate endothelial cells in vitro. Int J Cancer. 2004;110:807–814
  7. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001;61:2413–2419
  8. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–1280
  9. Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25:4722–4729
  10. Cloughesy T, MD P, Wen P, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). ASCO, J Clin Oncol. 2008;2010b
  11. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779–787

PII: S0959-8049(09)00816-8

doi: 10.1016/j.ejca.2009.10.029

European Journal of Cancer
Volume 46, Issue 2 , Pages 348-354 , January 2010

Article Tools

* Image Usage & Resolution